A Hybrid Intelligent System for Stamping Process Planning in Progressive Die Design

This paper presents an intelligent, hybrid system for stamping process planning in progressive die design. The system combines the flexibility of blackboard architecture with case-based reasoning. The hybrid system has the advantage that it can use past knowledge and experience for case-based reasoning when it exists, and other reasoning approaches when it doesn’t exist. A prototype system has been implemented in CLIPS and interfaced with Solid Edge CAD system. An example is included to demonstrate the approach.Singapore-MIT Alliance (SMA

Functional Modeling in Conceptual Die Design

The use of function has been recognized as an important part of the design process over last two decades, especially at the conceptual design stage, due to its critical role in determining the final product’s functionality. Although there are now some general methodologies dealing with functions or reasoning about functions, virtually no commercial CAD system can support conceptual design process due to their focus on geometrical modeling but not functional modeling. This paper presents a functional modeling approach to guide conceptual die design through functional reasoning steps including functional decomposition, functional supportive synthesis and function-structure mapping. The formed functional model provides a good basis to generate various die structures at the conceptual design stage, because function is a higher level of abstraction than structure, and helps to capture the designer’s intent. The functional modeling process has been implemented in a computerized design environment to expedite the conceptual die design process.Singapore-MIT Alliance (SMA

Functional design of mechanical products based on behavior-driven function-environment-structure modeling framework

The relative significance of upstream design activity to downstream design activity is widely recognized, due to its critical role in determining the final product’s functionality. Although there are now some general methodologies dealing with functions or reasoning about functions, virtually no commercial CAD system can support functional design. In functional modeling, a design problem is represented in a hierarchy of functions and the behaviors that realize the functions. This paper presents a functional design methodology based on a behavior-driven function-environment-structure (B-FES) modeling framework to guide functional design through functional reasoning steps including causal behavioral reasoning (CBR) and functional decomposition. The proposed functional design starts from a set of design specifications including functional requirements and design constraints, and results in diverse behavioral schema corresponding to a set of design alternatives. A design example for functional design of a terminal cut-off unit in an automatic assembly system is used to provide a demonstration of the proposed functional design methodology.Singapore-MIT Alliance (SMA

Association of Chinese Herbal Medicine use with the depression risk among the long-term breast cancer survivors: A longitudinal follow-up study

Background Breast cancer patients are at elevated risk of depression during treatment, thus provoking the chance of poor clinical outcomes. This retrospective cohort study aimed to investigate whether integrating Chinese herbal medicines citation(CHM) into conventional cancer therapy could decrease the risk of depression in the long-term breast cancer survivors. Methods A cohort of patients aged 20–70 years and with newly diagnosed breast cancer during 2000–2008 was identified from a nationwide claims database. In this study, we focused solely on survivors of breast cancer at least1 year after diagnosis. After one-to-one matching for age, sex, and baseline comorbidities, breast cancer patients who received (n = 1,450) and did not receive (n = 1,450) CHM treatment were enrolled. The incidence rate and hazard ratio citation(HR) for depression between the two groups was estimated at the end of 2012. A Cox proportional hazard model was constructed to examine the impact of the CHM use on the risk of depression. Results During the study period, the incidence rate of depression was significantly lower in the treated cohort than in the untreated cohort [8.57 compared with 11.01 per 1,000 person-years citation(PYs)], and the adjusted HR remained significant at 0.74 (95% CI 0.58–0.94) in a Cox proportional hazards regression model. The corresponding risk further decreasing to 43% among those using CHM for more than 1 year. Conclusion Finding from this investigation indicated that the lower risk of depression observed in breast cancer patients treated with CHM, suggesting that CHM treatment should be considered for disease management toward breast cancer. Yet, the optimal administered dose should be determined in further clinical trials

A Two-Step Quantum Direct Communication Protocol Using Einstein-Podolsky-Rosen Pair Block

A protocol for quantum secure direct communication using blocks of EPR pairs is proposed. A set of ordered $N$ EPR pairs is used as a data block for sending secret message directly. The ordered $N$ EPR set is divided into two particle sequences, a checking sequence and a message-coding sequence. After transmitting the checking sequence, the two parties of communication check eavesdropping by measuring a fraction of particles randomly chosen, with random choice of two sets of measuring bases. After insuring the security of the quantum channel, the sender, Alice encodes the secret message directly on the message-coding sequence and send them to Bob. By combining the checking and message-coding sequences together, Bob is able to read out the encoded messages directly. The scheme is secure because an eavesdropper cannot get both sequences simultaneously. We also discuss issues in a noisy channel.Comment: 8 pages and 2 figures. To appear in Phys Rev

The Yuan-Tseh Lee Array for Microwave Background Anisotropy

The Yuan-Tseh Lee Array for Microwave Background Anisotropy (AMiBA) is the first interferometer dedicated to studying the cosmic microwave background (CMB) radiation at 3mm wavelength. The choice of 3mm was made to minimize the contributions from foreground synchrotron radiation and Galactic dust emission. The initial configuration of seven 0.6m telescopes mounted on a 6-m hexapod platform was dedicated in October 2006 on Mauna Loa, Hawaii. Scientific operations began with the detection of a number of clusters of galaxies via the thermal Sunyaev-Zel'dovich effect. We compare our data with Subaru weak lensing data in order to study the structure of dark matter. We also compare our data with X-ray data in order to derive the Hubble constant.Comment: accepted for publication in ApJ (13 pages, 7 figures); a version with high resolution figures available at http://www.asiaa.sinica.edu.tw/~keiichi/upfiles/AMiBA7/pho_highreso.pd

The moderating effect of environmental dynamism on green product innovation and performance

Environmental management has been researching extensively in the last two decades. Pressure from environmental regulations or policies plays an important role to boost environmental management practices. Nevertheless, the relationship between such pressure and the ultimate firm performance is not very obvious. Although green product innovation has been recognized as a predictor to improve environment performance, there is a lack of discussion in the literature to examine the mediating effect of green product innovation between the aforementioned pressure and firm performance. Additionally, most previous studies adopted a static view which ignores the implications on external dynamic factors in many empirical studies. In this connection, this study contributes to the field of knowledge by filling these two gaps. More specifically, this study: (i) examines the effect of green product innovation on the relationship between pressure of environmental regulations (or policies) and firm performance; and (ii) evaluates the moderating effect of environmental dynamism on the relationship between green production innovation and firm performance. A questionnaire survey is conducted in an emerging country, China, to verify the hypotheses.Institute of Textiles and Clothin

FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium

Background:Breast cancer is one of the most common malignancies in women. Genome-wide association studies have identified FGFR2 as a breast cancer susceptibility gene. Common variation in other fibroblast growth factor (FGF) receptors might also modify risk. We tested this hypothesis by studying genotyped single-nucleotide polymorphisms (SNPs) and imputed SNPs in FGFR1, FGFR3, FGFR4 and FGFRL1 in the Breast Cancer Association Consortium. Methods:Data were combined from 49 studies, including 53 835 cases and 50 156 controls, of which 89 050 (46 450 cases and 42 600 controls) were of European ancestry, 12 893 (6269 cases and 6624 controls) of Asian and 2048 (1116 cases and 932 controls) of African ancestry. Associations with risk of breast cancer, overall and by disease sub-type, were assessed using unconditional logistic regression. Results:Little evidence of association with breast cancer risk was observed for SNPs in the FGF receptor genes. The strongest evidence in European women was for rs743682 in FGFR3; the estimated per-allele odds ratio was 1.05 (95 confidence interval=1.02-1.09, P=0.0020), which is substantially lower than that observed for SNPs in FGFR2. Conclusion:Our results suggest that common variants in the other FGF receptors are not associated with risk of breast cancer to the degree observed for FGFR2. © 2014 Cancer Research UK

Fine-Scale Mapping of the 5q11.2 Breast Cancer Locus Reveals at Least Three Independent Risk Variants Regulating MAP3K1

Peer reviewe

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362